熱門資訊> 正文
箭头因与萨雷普塔合作而陷入困境
2025-07-21 23:58
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) is down ~22% since market close on July 18 and the reason could be that the company has several early-stage candidates in partnership with recently belaguered Sarepta Therapeutics (NASDAQ:SRPT).
- Arrowhead closed July 19 down ~11% and is down another ~11% in late Monday morning trading.
- Sarepta and Arrowhead have four phase 1 candidates they are working on together: ARO-DUX4 for facioscapulohumeral muscular dystrophy type 1; ARO-DM1 for myotonic dystrophy type 1; ARO-ATXN2 for spinocerebellar ataxia 2; and ARO-ATXN2 for spinocerebellar ataxia 2
- Arrowhead also has two candidates in phase 3, but for cardiometabolic indications.
- Sarepta closed July 19 down ~36% after the U.S. FDA asked the company to voluntarily halt shipments of its Duchenne muscular dystrophy gene therapy Elevidys due to three patients deaths linked to the treatment. Sarepta has declined to do so.
- Earlier Monday, Sarepta disclosed that the FDA had issued clinical holds on trials for several candidates for limb girdle muscular dystrophy.
More on Arrowhead Pharmaceuticals
- Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade)
- Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript
- SA analyst downgrades: PLTR, PSTG, NTLA, ARWR
- Arrowhead targets 2025 plozasiran launch with $1.1B cash and clinical pipeline momentum
- Seeking Alpha’s Quant Rating on Arrowhead Pharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
